CN111698985B - 用于治疗乳腺癌和前列腺癌的组合物 - Google Patents

用于治疗乳腺癌和前列腺癌的组合物 Download PDF

Info

Publication number
CN111698985B
CN111698985B CN201880088898.9A CN201880088898A CN111698985B CN 111698985 B CN111698985 B CN 111698985B CN 201880088898 A CN201880088898 A CN 201880088898A CN 111698985 B CN111698985 B CN 111698985B
Authority
CN
China
Prior art keywords
dexamethasone
amount
composition
sevelanel
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880088898.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111698985A (zh
Inventor
E·巴斯金-贝
J·艾斯内尔
E·伍德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kabi Treatment Ltd
Original Assignee
Kabi Treatment Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Treatment Ltd filed Critical Kabi Treatment Ltd
Publication of CN111698985A publication Critical patent/CN111698985A/zh
Application granted granted Critical
Publication of CN111698985B publication Critical patent/CN111698985B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880088898.9A 2017-12-07 2018-12-06 用于治疗乳腺癌和前列腺癌的组合物 Active CN111698985B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762595918P 2017-12-07 2017-12-07
US62/595,918 2017-12-07
PCT/US2018/064229 WO2019113301A1 (en) 2017-12-07 2018-12-06 Compositions for the treatment of breast and prostate cancer

Publications (2)

Publication Number Publication Date
CN111698985A CN111698985A (zh) 2020-09-22
CN111698985B true CN111698985B (zh) 2023-10-31

Family

ID=66750338

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880088898.9A Active CN111698985B (zh) 2017-12-07 2018-12-06 用于治疗乳腺癌和前列腺癌的组合物

Country Status (8)

Country Link
US (2) US20210292410A1 (https=)
EP (1) EP3720427A4 (https=)
JP (1) JP7437576B2 (https=)
CN (1) CN111698985B (https=)
AU (1) AU2018380155B2 (https=)
CA (1) CA3084997A1 (https=)
TW (1) TWI809015B (https=)
WO (1) WO2019113301A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
US12357615B2 (en) 2018-10-11 2025-07-15 Kembi Therapeutics Pty Ltd Compositions for the treatment of brain tumors
CA3158748A1 (en) * 2019-10-25 2021-04-29 Garvan Institute Of Medical Research Methods of treating cancer using androgen receptor antagonists
US12150776B2 (en) * 2021-04-26 2024-11-26 Wisconsin Alumni Research Foundation & AIQ Solutions, Inc. System and method for monitoring multiple lesions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033004A3 (en) * 2011-08-30 2013-04-25 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DK0431519T3 (da) 1989-12-04 1994-07-04 Searle & Co System til transdermal indgivelse af albuterol
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
CA2755976C (en) 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
KR101848077B1 (ko) * 2010-11-13 2018-04-11 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
US20150005265A1 (en) * 2011-12-22 2015-01-01 Susan Stewart Methods and compositions for combination therapy using p13k/mtor inhibitores
PL2945628T3 (pl) * 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033004A3 (en) * 2011-08-30 2013-04-25 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A Polymorphismin the CYP17GeneIncreasesthe Risk of BreastCance;HeatherSpencerFeigelson et al.,;《cancer research》;19971231;全文 *
Tumour responses following a steroid switch;D Lorente et al.,;《British Journal of Cancer》;20141014;第111卷;摘要，第2250页 *

Also Published As

Publication number Publication date
JP2021505669A (ja) 2021-02-18
TWI809015B (zh) 2023-07-21
WO2019113301A1 (en) 2019-06-13
US20210154209A1 (en) 2021-05-27
AU2018380155B2 (en) 2024-07-04
CA3084997A1 (en) 2019-06-13
EP3720427A4 (en) 2021-09-15
JP7437576B2 (ja) 2024-02-26
CN111698985A (zh) 2020-09-22
AU2018380155A1 (en) 2020-07-02
US20210292410A1 (en) 2021-09-23
US11980626B2 (en) 2024-05-14
TW201938157A (zh) 2019-10-01
EP3720427A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
CN111698985B (zh) 用于治疗乳腺癌和前列腺癌的组合物
JP6564372B2 (ja) バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法
US8791094B2 (en) Treatment of prostate cancer
AU2020280272B2 (en) Methods of treating Chronic Spontaneous Urticaria using a Bruton's tyrosine kinase inhibitor
JP2019533660A (ja) 急性腎障害を処置する方法
CN111033634A (zh) 用于治疗纤维化疾病的化合物及其药物组合物
BR112018005771B1 (pt) Uso de um composto
JP2002523461A (ja) 神経変性疾患の治療方法
WO2020234780A1 (en) Methods of treating asthma using a bruton's tyrosine kinase inhibitor
EP4561574A1 (en) Dosing regimen for a nlrp3 inhibitor
US20250381179A1 (en) Chroman-based compounds for treating cancer
RU2847617C2 (ru) Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона
HK40126655A (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
JP2026509472A (ja) 喘息の治療のためのｊａｋ１経路阻害薬
HK40061328A (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
JP2025521628A (ja) カルシニューリン阻害剤の間欠的投与のための組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210430

Address after: Carlton, Australia

Applicant after: Kabi treatment Ltd.

Address before: North Carolina

Applicant before: Innolin Pharmaceutical Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant